GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: LPC-233 is an orally bioavailable preclinical antibacterial compound that inhibits bacterial UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC) and has potent activity against a wide range of Gram-negative bacteria in vitro [5].
|
|
No information available. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
The antibacterial MMOA is competitive inhibition of LpxC [5], which is an essential enzyme in the biosynthesis of lipid A (also know as endotoxin), the hydrophobic anchor of lipopolysaccharide (LPS) and a major component of the outer membrane of Gram-negative bacteria [3-4]. LpxC is an attractive target for the development of antibacterial agents against Gram-negative bacterial pathogens, although safety and activity issues have so far precluded approval for clinical use of these drugs [1-2]. |